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Abstract: In hospitals, a major part of the drugs is admi-
nistered via the intravenous route. When one wants to
evaluate or know the stability of a drug in solution, it is
necessary to know several physico-chemical parameters.
Several reference works are available to help the hospi-
tal pharmacist with this research. However, reading
these different sources can make you discover conflict-
ing data. It is therefore necessary at this time to obtain
the publications with contradictory results and to read
them again. Seven criteria have been identified for jud-
ging the quality of a publication on physicochemical
stability: full description of equipment, methods and
analytical conditions of molecules studied; complete
description of the procedures used to validate the
analytical method; full indication of time testing and
measurement bases or control; documentation on the
analytical reproducibility; adequate statistical analysis;
appropriate conclusions; appropriate references. In
conclusion, everything in a compatibility study is
important.
Keywords: physico-chemical stability, injectable drugs,
drug stability, CIVAS
Introduction
In hospitals, a major part of the drugs is administered via
the intravenous route. Several authors tried to quantify
the quantity of injectables administered to the patients.
Turco SJ [1] reports that 24% of the administered
doses in the hospital are injectable drugs, just as 38%
of the patients receive at least an injection per day.
According to Simons BP [2], 30 to 50% of the patients
receive medications via the intravenous route, a percen-
tage confirmed by Taxis K (28%), Bernaerts K (34%) and
Champion K (23 to 25%) [3–5].
Kwan JW [6] estimates that 40% of medications and
solutions are administered via the intravenous route
while Rwabihama JP [7] notes that 49% of the patients
are under perfusion.
Recently, Fekadu et al reported that 50%, 32.1% and
12.7% of patients receive two, three or four intravenous
drugs per prescription, respectively [8].
When one wants to evaluate or know the stability of
a drug in solution, it is necessary to know: final concen-
tration of the reconstituted product, nature, pH and ionic
force of the diluent, pH and ionic force of final dilution,
nature of the container (polyvinyl chloride (PVC), ethyl-
vinyl acetate (EVA), polypropylene, …) to avoid the phe-
nomenon of sorption and salting out, conditions of
storage (refrigerator, ambient temperature, body tem-
perature, protection from light), nature of the set of
administration (PVC, polyethylene, …), protection from
light during the administration [9].
Which healthcare professional may answer to these
questions? Hasegawa gives the response in 1994: “Caring
about stability and compatibility may not excite many
pharmacists. However, no other health professionals are
as qualified or as obligated to effectively apply their
training and experience and the abundance of published
data to this aspect of patient care” [10].
Several reference works are available to help the
hospital pharmacist with this research [11–19] and have
been evaluated [20].
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However, reading these different sources can make
you discover conflicting data.
It is therefore necessary at this time to obtain the pub-
lications with contradictory results and to read them again.
Guidelines are available to perform stability studies
[21]. However, they have been designed for purposes not
entirely covering the practical needs [22].). Indeed, ICH
guidelines have the objective to regulate the quality of
marketed drugs in an international context and pharma-
copeia monographs often refer to raw materials and offer
no solution when applied to marketed products under
practical conditions [22].
Some papers have been published to approach field
practice [22–25].
Criteria for judging the quality of
a publication on physicochemical
stability
A review of the literature on this subject identified some
papers written by different authors, and seven criteria have
been identified: full description of equipment, methods and
analytical conditions of molecules studied; complete
description of the procedures used to validate the analytical
method; full indication of time testing and measurement
bases or control; documentation on the analytical reprodu-
cibility; adequate statistical analysis; appropriate conclu-
sions; appropriate references [26–34]
Description of the preparation and storage
of the ready to use or ready to administer
drugs
The following information must be specified: complete
drug formulation, manufacturer and batch number of the
molecules, the solutions and the containers.
Indeed, similar products from different suppliers may
have differing formulations that can affect results.
The method of reconstitution must be described, with
the conditions of environment: under laminar air flow cabi-
netor isolator, under clinical conditions, in thewardareaetc.
Full description of equipment, methods and
analytical conditions of molecules studied
High performance liquid chromatography (HPLC) is the
most important used method. Alternatives are capillary
electrophoresis and high performance thin layer chroma-
tography [23].
The following information must be specified: manu-
facturer and batch number of the chemicals, identifica-
tion of equipment and devices, of other equipment used
for the analysis (pH meter, microscope, spectrophot-
ometer etc.). Solution preparations, standard solutions,
quality-control solutions, chromatographic conditions,
pH determination must also be specified, ideally in sepa-
rate subtitles, to permit the replication of the study.
The temperature of storage must be specified: deep
freezing: < - 15 °C; refrigerator: 2 to 8 °C, cool temperature:
8 to 15 °C, room temperature: 15 to 25 °C.
To increase their period of validity, some drug solu-
tions are frozen. The method of thawing must be
described with precision: room temperature, bags in a
laminar flow to a constant renewal of the air at the sur-
face of the bag, water bath, forced ventilation air fan,
microwave oven [35].
If only the words “room temperature” are specified,
the reader will refer to the country and the climatic zone
in which the study was carried out.
The World Health Organization has defined 5 climatic
zones and respective climatic conditions [36]. Mean
annual temperature can vary from 20 °C (Zone I) to
26.7 °C (Zone IV). The temperature of use may also be
described: room temperature, skin temperature (30 to
32 °C), body temperature (36.1 to 37.8 °C).
If the pharmacist has a climate chamber, stability
testing is performed at 25 °C while maintaining the resi-
dual moisture at 60 ± 5%, in order to achieve the con-
ditions recommended by the ICH [21]. Otherwise, the
study will be conducted under local residual moisture
conditions, and it is recommended that measurement is
taken regularly ([23].
The duration of the drug administration is also
important for the duration of the physico-chemical
stability.
Most products are exposed to light, particularly
during prolonged administration regimens. Ensuring
that the product is stable when exposed to light is an
imperative condition, especially for products known to
be light-sensitive. Storing samples in an open labora-
tory environment, subject to diffuse daylight and fluor-
escent room lighting will detect any serious light
stability problems. Comparisons should be made to
control samples, stored at the same time but protected
from light [37].
Intravenous drug solutions are stored in plastic con-
tainers. The term “plastic” is not sufficiently precise. The
European Pharmacopeia gives a full description of the
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different plastics: polyolefines, polyethylene without
additives for containers for preparations for parenteral
and for ophthalmic preparations, polyethylene with addi-
tives for containers for preparations for parenteral and for
ophthalmic preparations, polypropylene for containers
and closures for parenteral and ophthalmic preparations,
poly(ethylene–vinylacetate) for containers and tubing for
total parenteral nutrition preparations, silicone oil used
as a lubricant, silicone elastomer for closures and tubing,
plastic additives, materials based on plasticized PVC for
containers for aqueous solutions for IV-infusion [38].
Complete description of the procedures used
to validate the analytical method
This section must include documentation which confirms
that the analytical method is “stability indicating”: valida-
tion of HPLC method and stability indication; the HPLC
assay must be described and illustrated: calibration curve,
chromatograms, calculations (references of the software).
It must be demonstrated that the method can distin-
guish between the parent substance and its degradation
products, but also any other products present in the
solution.
A stability indicating-assay is a validated quantitative
analytical method that can detect the changes over time
in the chemical or physical properties of the drug sub-
stance, and that are specific so that active ingredient,
degradation products, and other components of interest
can be accurately distinguished without interference. The
assay must establish that there is no interference of the
assay by vehicles or degradation by-products and usually
involves forced degradation of the parent chemical to
determine the nature and chromatographic peak of
degradation by-products and other excipients.
The validation of an analytical method can involve
the analysis of several parameters such as the specificity,
precision, accuracy etc.: the specificity is the degree to
which the method can quantify the analyte of interest
accurately in presence of components which may be
expected to be present. The accuracy expresses the close-
ness of agreement between the value which is accepted
either as a conventional true value or an accepted refer-
ence value and the value found, and the precision spe-
cifies the closeness of agreement between a series of
measurements obtained from multiple sampling of the
same homogeneous sample under the prescribed condi-
tions. The precision includes the within (same conditions
of measurements) and between (variation in conditions
among runs) days reproducibility. The precision is
usually expressed as the variance, standard deviation or
coefficient of variation of a series of measurements.
The presence of particles has to be searched by micro-
scopic analysis with a detection level of 500 nm, currently
used for the medical particles measurement [38].
Documentation on the analytical
reproducibility
Investigators should provide documentation indicating
the reproducibility of their method to ensure that their
method can easily discern the slightest change in
concentration.
Full indication of time testing
and measurement bases or control
The publication must mention full indication of time
testing and measurement bases or control.
If an initial measurement (time zero) is not reported in
the stability study, the conclusions concerning the stability
of the compound cannot be made with confidence.
Biological products like monoclonal antibodies con-
stitute a special case. Because of their protein nature,
these molecules may go through a variety of chemical
and degradation processes. The long term stability of
reconstituted drugs must be certified by several analyses
as, for example, turbidimetric determination by UV-VIS
spectrophotometry, tertiary structure analysis by second
derivative UV spectroscopy, determination of molecular
hydrodynamic diameters by dynamic light scattering
(DLS), thermal denaturation curves by DLS, secondary
structure analysis by second derivative FR-IR spectro-
scopy, chromatographic analysis (cation exchange chro-
matography, size-exclusion chromatography etc.) [39–44]
Adequate statistical analysis
In the absence of toxic degradation products, or physical
changes, the end of a product’s shelf life is often assumed
as when the content reaches 90% of the label claim. The
best approach to analyze all the data points is based
upon regression analysis. For most drugs, the degrada-
tion follows a first-order kinetic. As recommended by the
Food and Drug Administration, it is classical to base the
expiry time on the one-sided lower 95% confidence limit
of the regression line [45]. However, this view is now
challenged by some authors [46].
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Appropriate conclusions
The conclusions should reflect the overall results
observed in the document and must be in accordance
with these results.
A drug solution cannot be certified “stable” if physi-
cal stability and chemical stability have not been studied
jointly: these two types of stability are complementary; a
physically stable product is not necessary chemically
stable and vice versa.
The observed results cannot be extrapolated ipso
facto to other storage conditions not studied in the
publication.
The Stabilis database [18] has recently been enriched
with a rating grid for anticancer molecules. The scale is
“A” (visual inspection, HPLC with diode array detector
with over 95% initial concentration, measured pH and no
degradation product observed under actual conditions()
to D (established stability with 90% of initial concentra-
tion but separative method with one or more failing
criteria OR stability established with 95% of the initial
concentration but separative method with more than 2
criteria failing OR unjustified choice of a method other
than HPLC and stability established with 90% of initial
concentration).
Appropriate references
Before starting their study, the authors made sure that
it had not already been carried out by another research
team, by a review of the literature. This review of the
literature will be included in the references and com-
mented in the discussion. This review should be as
exhaustive as possible and contain the original publi-
cations and not only the comments of these original
publications.
Conclusion
This review of criteria should help the reader to judge a
publication of physico-chemical stability.
Some databases also show a level of proof by stabi-
lity study and, to use the title of two publications by
L Trissel, “Everything in a compatibility study is impor-
tant” and “Don’t ignore details of drug-compatibility
reports”. If they are not very recent, they nevertheless
remain current.
Conflict of interest statement: Authors state no conflict
of interest. All authors have read the journal’s
Publication ethics and publication malpractice statement
available at the journal’s website and hereby confirm that
they comply with all its parts applicable to the present
scientific work.
References
1. Turco SJ. Parenteral admixtures and incompatibilities. Sterile
dosage forms. Their preparation and clinical application,
4th ed. Baltimore MD: Lippincott Williams & Wilkins,
1994:239.
2. Simmons BP. CDC Guidelines for the prevention and control of
nosocomial infections, Guideline for prevention of intravascu-
lar infections. Am J Inf Control 1983;11:183–199.
3. Takis K, Barber N. Ethnographic study of incidence and
severity of intravenous drug errors. Br Med J 2003;326:
684–690.
4. Bernaerts K, Evers G, Sermeus W. Frequency of intravenous
medication administration to hospitalized patients: Secondary
data-analysis of the Belgian nursing minimum data set. Int J
Nurs Stud 2000;37:101–110.
5. Champion K, Mouly S, Lloret-Linares C, Lopes A, Vicaut E,
Bergmann JF, PERMI Investigators Committee. Optimizing the
use of intravenous therapy in internal medicine. Am J Med.
2013;126:925:e1–9.
6. Kwan JW, Anderson RW. Pharmacists’s knowledge of infusion
devices. Am J Hosp Pharm 1991;48:S52–53.
7. Rwabihama JP, Aubourg R, Oliary J, Mouly S, Champion K,
Leverge R et al. Usage et mésusage de la voie intraveineuse
pour l’administration de medicaments en medicine interne.
Press Med 2006;35:1453–1460.
8. Fekadu T, Teweldemedhin M, Esrael E, Asgedom SZW.
Prevalence of intravenous administration erros: A cross-
sectional study. Integr Pharm Res Practice 2017;6:47–51.
9. Hecq JD. Centralized Intravenous Additive Services (CIVAS):
The state of the art in 2010. Ann Pharm Fr 2011;69:30–37.
10. Hasegawa R. Caring about stability and compatibility.
Am J Hosp Pharm 1994;51:1533–1534.
11. Bing CM. Extended stability for parenteral drugs, 5th ed.
Bethesda, MD: ASHP 2013.
12. Catania PN King Guide to parenteral admixtures, 45th ed.
Napa, CA: King Guide Publications, 2016 www.kingguide.com.
13. Hecq JD Stabilité des médicaments injectables en perfusion.
ABPH-BVZA - Bruxelles 2016.
14. Husson MC, Vigneron J, Astier A, Pinguet F, Rizzo-Padouin N,
Dumont A, et al. Monographies In Anticancéreux: utilisation
pratique 7ème édition. Dossier du CNIMH XXXIV, 5–6
décembre 2013.
15. Morris N. Australian Handbook injectable drugs, 6th ed.
Collingwood: Society of Hospital Pharmacist of Australia, 2014.
16. Needle R, Sizer T. The Civas Handbook. London:
Pharmaceutical Press, 1998.
17. McEvoy GK. Handbook on injectable drugs, 19th ed. Bethesda,
MD: ASHP, 2017.
82 J.-D. Hecq et al.: Criteria for Judging the Quality of a Publication
18. Vigneron J. Stabilis Website. www.stabilis.org.
19. Micromedex database www.micromedexsolutions.com/micro
medex2/librarian.
20. Smith WD, Karpinski JP, Timpe EM, Hatton RC. Evaluation of
seven iv drug compatibility references by using requests from
a drug information center. Am J Health Syst Pharm
2009;66:1369–1375.
21. ICH Harmonised Tripartite Guidelines. Validation of analytical
procedures Q2(R1) http://www.ich.org/products/guidelines/
quality/article/quality-guidelines.html
22. Bardin C, Astier A, Vulto A, Sewell G, Vigneron J, Trittler R,
et al. Guidelines for the practical stability studies of anticancer
drugs: A european consensus conference. Ann Pharm Fr
2011;69:221–231.
23. Sautou V, Brossard D, Chedru-Legros V, Crauste-Manciet S,
Fleury-Souverain S, Lagarce F, et al. Methodological guidelines
for stability studies of hospital preparations, 1st ed. Pau: SFPC
and GERPAC, 2013.
24. Santillo M, Aiyalu S, Austin P, Barnes A, Goddard W, Hiom S,
et al. A standard protocol for deriving and assessment of
stability – Part 1: Aseptic preparations (small molecules) NHS
3rd ed. December 2015.
25. Santillo M, Barnes A, Douris G, Goddard W, Hiom S, Jackson M,
et al. Part 2: Aseptic preparations (Biopharmaceuticals) NHS
1st ed. October 2012.
26. Klang MG. Evaluating intravenous compatibility literature.
New-York Health-System Pharmacist 2002;21:4–7.
27. Prankerd RJ. Practical aspects of the stability testing of for-
mulated drug products. Aust J Hosp Pharm 1995;25:405–408.
28. Prankerd RJ. Compounded products – Stability studies in hos-
pital pharmacy departments. J Pharm Pract Res 2009;39:5–7.
29. Trissel LA. Avoiding common flaws in stability and compat-
ibility studies of injectable drugs. Am J Hosp Pharm
1983;40:1159–1160.
30. Trissel LA, Flora KP. Stability studies: Five years later. Am J
Hosp Pharm 1988;45:1569–1571.
31. Vigneron J. Stability studies: Ten pieces of advice. Ejhp-S 2008;1:2.
32. Williams LV, Hastings MB. Identifying the criteria of a valid
stability study. Int J Pharm Compound 2009;13:32–36.
33. Trissel LA. Everything in a incompatibility study is important.
Am J Health Syst Pharm 1996;53:2990.
34. Kohut J, Trissel LA, Leissing NC. Don’t ignore details of
drug compatibility reports. Am J Health Syst Pharm
1996;53:2339.
35. Hecq JD, Godet M, Jamart J, Galanti L. Microwave freeze-thaw
technique of injectable drugs. A review from 1980 to 2014. Ann
Pharm Fr 2015;73:436–441.
36. Kaur M, Kaur G, Kaur H, Sharma S. Overview on stability
studies. Int J Pharm Chem Biol Sci 2013;3:1231–1241.
37. Barnes AR. Near-patient stabilities. J Clin Pharm Ther
1996;21:49–55.
38. De Jong JHJ. European Pharmacopeia, 7th ed. 2000.
Strasbourg, France.
39. Paul M, Vieillard V, Roumi E, Cauvin A, Despiau MC, Laurent M,
et al. Long-term stability of bevacizumab repackaged in 1 ml
polypropylene syringes for intravitreal administration. Ann
Pharm Fr 2012;70:139–154.
40. Paul M, Vieillard V, Jaccoulet E, Astier A. Long-term stability of
diluted solutions of the monoclonal antibody rituximab. Int J
Pharm 2012;436:282–290.
41. Paul M, Vieillard V, Da Silva Lemos R, Escalup L, Astier R. Long-
term physico-chemical stability of diluted trastuzumab. Int J
Pharm 2013;448:101–104.
42. Bardo-Brouard P, Vieillard V, Shekarian T, Marabelle A,
Astier A, Paul M. Stability of ipilimumab in its original vial after
opening allows its use for at least 4 weeks and facilitates pooling
of residues. European Journal of Cancer 2016;58:8–16.
43. Vieillard P, Astier A, Sauzay C, Paul M. One-month stability study
of a biosimilar of infliximab (Remsima) after dilution and storage
at 4 °C and 25 °C. Ann Pharm Fr 2017;75:17–29.
44. International conference on harmonization of technical
requirements for registration of pharmaceuticals for human
use. ICH tripartite harmonized guideline, Quality of biotech-
nological products: stability testing for biotechnological/bio-
logical products Q5C. https://www.ich.org/fileadmin/Public_
Web_Site/ICH_Products/Guidelines/Quality/Q5C/Step4/Q5C_
Guideline.pdf Accessed: 26 May 2017.
45. U.S. Department of Health and Human Services. U.S.
Food and Drug Administration. Center for Drug Evaluation
and Research. Center for Drugs and Biologics. Guideline
for Submitting Documentation for the Stability of
Human Drugs and Biologics. Rockville, MD: U.S. Food
and Drug Administration, 1987: 1–56. [FDA Website]
February 1987.
46. Bihin B, Hecq JD, Godet M, Galanti L, Jamart J Toward new
statistical methods to determine the shelf-life of injectable
drugs. International symposium on infusion technologies.
9th–10th novembre 2016, Lille France.
Bionotes
Jean-Daniel Hecq
Department of Hospital Pharmacy, CHU UCL
Namur, Avenue G. Thérasse 1, Yvoir 5530,
Belgium, uss-chu@uclouvain.be
Professor Jean-Daniel Hecq is a hospital pharmacist and doctor in
pharmaceutical sciences. He has been working at the CHU UCL
Namur since 1979 and is chief of the department of Pharmacy since
1989. He is also the coordinator of the Drug Stability Research
Group in the same CHU and since 35 years the author of a Belgian
electronic database entitled “Stability of injectable drugs in
infusion”.
J.-D. Hecq et al.: Criteria for Judging the Quality of a Publication 83
Benoit Bihin
Scientific Support Unit, CHU UCL Namur,
Yvoir, Belgium, benoit.bihin@uclouvain.be
Benoit Bihin is a biologist. Being a PhD Student at the University of
Namur since 2011, he is also a lecturer for biostatistics courses. He
has been working at the CHU UCL Namur as biostatistician since
2014 and is a member of the Drug Stability Research Group.
Jacques Jamart
Scientific Support Unit, CHU UCL Namur,
Yvoir, Belgium, Jacques.jamart@uclouvain.be
Jacques Jamart is a medical doctor (1972) and surgeon (1978) with a
master’s degree in statistics (1984). He has worked in experimental
surgery, mainly in the field of organ preservation for transplantation
and more recently as biostatistician and head of the Scientific
Support Unit (1993) of the University Hospital of Mont-Godinne. He
is also a professor at the Catholic University of Louvain (2009) and
at the University of Namur (2010).
Laurence Galanti
Medical Laboratory, CHU UCL Namur, Yvoir,
Belgium, laurence.galanti@uclouvain.be
Professor Laurence Galanti, MD, PhD is co-director of the
department of laboratory medicine at CHU UCL Namur, in charge of
clinical biochemistry on the site of Mont-Godinne. She holds several
positions in national and international scientific organizations. Her
research is focused on clinical application of biomarkers of
exposition to tobacco smoke and on the stability of injectable drugs
in collaboration with the department of pharmacy.
84 J.-D. Hecq et al.: Criteria for Judging the Quality of a Publication
